Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02437136
Title Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma
Recruitment Unknown status
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Syndax Pharmaceuticals


lung non-small cell carcinoma


Entinostat + Pembrolizumab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Yale University New Haven Connecticut 06519 United States Details
Emory University Atlanta Georgia 30322 United States Details
University of Maryland, Marlene and Stewart Greenbaum Cancer Center Baltimore Maryland 21201 United States Details
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland 21231 United States Details
Dana Farber Cancer Institution Boston Massachusetts 02215 United States Details
Roswell Park Cancer Institute Buffalo New York 14263 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
The University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599 United States Details
St Luke's University Health Network Easton Pennsylvania 18045 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
Vanderbilt University Medical Center Nashville Tennessee 37230 United States Details
*Shaded cells indicate that there was no data available from for the field